Clinitech Laboratory Ltd (CTLLAB) — shareholding pattern, promoter holding, financials and share price
About Clinitech Laboratory Ltd (CTLLAB)
Clinitech Laboratory Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as CTLLAB and on the BSE under scrip code 544220. Its ISIN is INE0QMR01015.
Incorporated in 1990, Clinitech Laboratory Ltd is in the business of providing pathology and related healthcare services. [1]
Clinitech Laboratory Limited is a provider of diagnostic and healthcare tests and services through a chain of 8 diagnostic centers around Thane, Raigad, and Navi Mumbai.
The company performs over 300,000 tests annually, including a wide range of laboratory diagnostics like biochemistry, immunology, and molecular biology in NABL-accredited labs.
Listed peers in Healthcare Service Provider: Dhanvantri Jeevan Rekha Ltd, Looks Health Services Ltd, Dr Lalchandani Labs Ltd, Ashram Online.com Ltd, Gian Lifecare Ltd, Boston Commerce Limited.
Valuation & Returns
10 Jul 2026At ₹40 a share on 10 Jul 2026, Clinitech Laboratory Ltd (CTLLAB) was valued at a price-to-earnings ratio of 21.86x against an industry P/E of 61.73x and a price-to-book of 0.99x on a book value of ₹40.54 per share. Solomo computes return on equity of 4.52% and return on capital employed of 6.8% from filed results.
- P/E
- 21.86x
- Industry P/E
- 61.73x
- P/B
- 0.99x
- EPS (TTM)
- ₹1.83
- Book value / share
- ₹40.54
- ROE
- 4.52%
- ROCE
- 6.8%
- ROA
- 3.67%
- Debt / equity
- 0.06x
- Dividend yield
- 0%
- EBITDA margin
- 12.43%
- 52-week range
- ₹28.55 – ₹57
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Clinitech Laboratory Ltd (CTLLAB) reported revenue of ₹9.49 crore, net profit of ₹0.42 crore and earnings per share of ₹1.84. That compares with revenue of ₹8.23 crore and net profit of ₹0.39 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹4.41 crore and net profit ₹0.12 crore (consolidated).
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue (₹ cr) | 8.23 | 9.49 |
| Net profit (₹ cr) | 0.39 | 0.42 |
| EPS (₹) | 1.71 | 1.84 |
| Measure | 3Y | 1Y |
|---|---|---|
| Sales growth | 8.85% | 28.59% |
| Profit growth | -8.34% | 5.41% |
| Stock price CAGR | - | 18% |
Ownership Summary
Mar 2026As of Mar 2026, promoters hold 64.2% of Clinitech Laboratory Ltd (CTLLAB), foreign institutional investors (FII) hold 0.32%. Market capitalisation was ₹9 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2024.
Largest disclosed public shareholders in Mar 2026: SANTOSH GOPALKRISHNA KUDVA 5.84%, KRISHA V TALREJA 3.1%, AJIT SAKHARAM KANDAR 2.24%, SHIRISH NANUBHAI PATEL 1.58%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Mar 2026 | 64.2% | - | 0.32% | - | 35.8% |
| Sep 2025 | 62.42% | - | 0.32% | - | 37.58% |
| Mar 2025 | 61.58% | - | 0.32% | - | 38.42% |
| Sep 2024 | 61.58% | - | 0.32% | - | 38.42% |